Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €132.26 EUR
Change Today -0.352 / -0.27%
Volume 370.0
BM8 On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 1:44 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

biomarin pharmaceutical inc (BM8) Snapshot

Open
€131.63
Previous Close
€132.61
Day High
€136.90
Day Low
€129.47
52 Week High
07/20/15 - €140.53
52 Week Low
08/8/14 - €46.78
Market Cap
21.2B
Average Volume 10 Days
242.3
EPS TTM
--
Shares Outstanding
160.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOMARIN PHARMACEUTICAL INC (BM8)

biomarin pharmaceutical inc (BM8) Details

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including drisapersen, an exon-51 skipping compound for the treatment of Duchenne muscular dystrophy (DMD); pegvaliase, an enzyme substitution therapy for the treatment of PKU; reveglucosidase alfa, an enzyme replacement therapy for Pompe disease; talazoparib, an orally available poly-ADP ribose polymerase inhibitor for cancer treatment; BMN 111, a peptide therapeutic for achondroplasia treatment; BMN 044, BMN 045, and BMN 053 for DMD treatment; and cerliponase alfa for the treatment of late infantile neuronal ceroid lipofuscinosis. In addition, it develops preclinical product candidates for genetic and other metabolic diseases, such as BMN 270 and BMN 250. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. S.A. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation; and an agreement with Merck Serono. The company was founded in 1996 and is headquartered in San Rafael, California.

1,681 Employees
Last Reported Date: 03/2/15
Founded in 1996

biomarin pharmaceutical inc (BM8) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $916.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $480.6K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $528.2K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $417.7K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $409.6K
Compensation as of Fiscal Year 2014.

biomarin pharmaceutical inc (BM8) Key Developments

BioMarin Pharmaceutical Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Year 2015; Announces Impairment Charges for the Second Quarter of 2015

BioMarin Pharmaceutical Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $250,523,000 against $191,787,000 a year ago. This increase was driven by solid growth across all BioMarin products including Kuvan, Naglazyme and Vimizim. Sales of Vimizim, now in its fifth full quarter of sales since being approved in early 2014, were recorded in 30 countries in the second quarter and totaled $53.9 million. Loss from operations from operations was $64,240,000 against $18,882,000 a year ago. Loss before income taxes was $82,544,000 against $27,728,000 a year ago. Net loss was $81,989,000 against $33,502,000 a year ago. Basic and diluted loss per share was $0.51 against $0.23 a year ago. Non-GAAP loss from operations was $8.9 million against non-GAAP income from operations $11.4 million a year ago. Non-GAAP loss before income taxes was $5.4 million against non-GAAP income before income taxes $10.1 million a year ago. Non-GAAP net loss was $5.4 million against non-GAAP net income of $10.1 million a year ago. The increased non-GAAP net loss and GAAP net loss for the second quarter of 2015 compared to the second quarter of 2014 was primarily due to increased operating expenses, partially offset by increased revenues due to the strong commercial launch of Vimizim. For the six months, the company reported total revenues of $453,787,000 against $343,339,000 a year ago. Loss from operations from operations was $130,101,000 against $45,338,000 a year ago. Loss before income taxes was $157,246,000 against $62,352,000 a year ago. Net loss was $149,490,000 against $71,617,000 a year ago. Diluted and basic loss per share was $0.94 against diluted loss per share of $0.50 a year ago. Non-GAAP loss from operations was $34.0 million against non-GAAP income from operations $9.9 million a year ago. Non-GAAP loss before income taxes was $30.6 million against non-GAAP income before income taxes $8.4 million a year ago. Non-GAAP net loss was $30.6 million against non-GAAP net income of $8.4 million a year ago. For the year ending December 31, 2015, the company expects total revenues to be $850 million to $880 million, GAAP net loss to be $360 million to $400 million, non-GAAP net loss to be $130 million to $170 million. The company expects interest expense, net of $35.3 million, depreciation expense of $38.4 million, amortization expense of $12.4 million. On a constant currency basis, guidance for total revenues in 2015 would be $880 million to $920 million. The company announced impairment charges of $12.8 million for the second quarter ended June 30, 2015.

BioMarin Pharmaceutical Announces Positive Results from Phase II ABRAZO Study

BioMarin Pharmaceutical Inc. announced positive results from the Phase II ABRAZO study with its poly ADP-ribose polymerase, or PARP, inhibitor, talazoparib, for the treatment of patients with deleterious germline BRCA 1 or BRCA 2 mutations and locally advanced and/or metastatic breast cancer. The company announced that the ABRAZO Phase II trial has met the study's protocol-specified threshold for documented tumor reduction (using the RECIST response rate criteria) in order to warrant expanding enrollment in the study from 70 to 140 patients. The ABRAZO study includes two cohorts of patients with BRCA mutated metastatic breast cancer. The first cohort consists of patients who have initially responded to a platinum-containing regimen then progressed, while the second cohort consists of patients who have received more than two prior chemotherapy regimens for metastatic disease. The protocol-specified expansion criteria requires that a minimum of five responses per cohort, of up to 35 patients, be observed in order to expand the study. The minimum of 5 responses was seen prior to full enrollment in each cohort. The ABRAZO study is the first study treating BRCA breast cancer patients with a PARP inhibitor monotherapy that has demonstrated activity in patients who are in a salvage setting defined as having failed at least two prior chemotherapy regimens for metastatic disease. In addition, this is the first reported data showing tumor reduction from a PARP inhibitor in BRCA breast cancer patients previously treated with a platinum regimen. The trial, now targeting enrollment of a total of 140 patients, is expected to be fully enrolled in the first quarter of 2016 with results expected by year end 2016. EMBRACA is a Phase III, open-label, 2:1 randomized trial to compare the safety and efficacy of oral PARP inhibitor talazoparib versus protocol-specific physician's choice in patients who have locally advanced and/or metastatic breast cancer with germline BRCA mutations. Prior guidance had been for enrollment of 430 patients by year end 2015. Since study initiation, a newly completed review of published data suggests that the median progression-free survival (PFS) is lower than originally estimated for the control arm in this patient population, and that fewer than the originally estimated 430 patients may need to be enrolled in order to achieve the targeted hazard ratio. This is a Phase II, 2-Stage, 2-Cohort Study of oral PARP inhibitor talazoparib (BMN 673) in patients with locally advanced and/or metastatic breast cancer with germline BRCA mutations. Subjects will be assigned to either Cohort 1 or 2 based on prior chemotherapy for metastatic disease: Cohort 1 include subjects who have previously responded (PR or CR) to a platinum-containing regimen for metastatic disease with disease progression > 8 weeks following the last dose of platinum; and Cohort 2 include subjects who have received more than two prior chemotherapy regimens for metastatic disease and no prior platinum therapy for metastatic disease. This is a Phase III, open-label, 2:1 randomized trial to compare the safety and efficacy of oral PARP inhibitor talazoparib (BMN 673) versus protocol-specific physician's choice in patients who have locally advanced and/or metastatic breast cancer with germline BRCA mutations. The primary objective of the study is to compare progression-free survival (PFS) of subjects treated with talazoparib (BMN 673) as a monotherapy relative to those treated with protocol-specific physician's choice. The secondary objectives are to evaluate objective response rate (ORR) and overall survival (OS). Exploratory objectives are to evaluate duration of response (DOR) and health-related quality of life.

BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) added to NASDAQ-100 Index

BioMarin Pharmaceutical Inc. has been added to NASDAQ-100 Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BM8:GR €132.26 EUR -0.352

BM8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $70.25 USD -0.08
Incyte Corp $109.74 USD +5.76
Jazz Pharmaceuticals PLC $190.66 USD -2.11
Momenta Pharmaceuticals Inc $22.05 USD +0.29
Vertex Pharmaceuticals Inc $140.30 USD +3.31
View Industry Companies
 

Industry Analysis

BM8

Industry Average

Valuation BM8 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 27.4x
Price/Book 10.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 25.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOMARIN PHARMACEUTICAL INC, please visit www.bmrn.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.